Not Signed In - Immtech Completes Enrollment In Phase III Pivotal Trial Of Pafuramidine For African Sleeping Sickness
Wed, 31 Jan 2007 08:00 AM EST
... Immtech Pharmaceuticals, Inc. (Amex: IMM) announced today that it has completed enrollment in a Phase III pivotal trial of its oral drug candidate, pafuramidine maleate (pafuramidine), to treat first-stage patients (those with no evidence of central nervous system involvement) for African trypanosomiasis, also known as African sleeping sickness. [click link for full article] ...
Related Topics
- Sleeping Sickness
- African Trypanosomiasis
- Clinical Trials
- Motion Sickness
- African American
- African-American Health
- Antithrombin III
- Acetazolamide
- Familial Dysautonomia
- African American / Black Women
- Food Recommendations: South Beach Diet - Phase 2
- Food Recommendations: South Beach Diet - Phase 1
- Trypanosomiasis, African
- Congenital antithrombin III deficiency
- Cranial mononeuropathy III - diabetic type
- Cranial mononeuropathy III - compression type
- Antithrombin
- Radiation sickness
- Altitude Sickness
- Serum Sickness
email this page
print this page
bookmark this page
feedback on this page
